% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • theman3311 theman3311 Jul 1, 2013 1:15 PM Flag

    Synta Pharmaceuticals Corp. Research Report

    "Outside of certain genetically-defined patient populations, there have been no new options for the treatment of patients with non-small cell adenocarcinoma following first-line therapy in nearly a decade," said Dr. Dean A. Fennell, University Hospital, Leicester, UK, co-Principal Investigator of GALAXY-1. He further added, "The magnitude and consistency of the activity reported today are very encouraging and bode well for the outcome of the GALAXY-2 Phase 3 study."

    Sentiment: Strong Buy

0.4564+0.0175(+3.99%)Nov 25 4:00 PMEST